Literatur
Abrahamsson P, Cochett ATK, di Sant’Agnese PA (1998) Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate 8: 37–42
Amato R, Wyothetis CJ, Halliman R, Ro JY, Sella A, Dexeus FH (1992) Chemotherapy for small cell carcinoma of prostatic origin. J Urol 147: 935–937
Apikian AG, Cordon-Cardo C, Fair WR, Zhang Z, Bazinot M, Handy SM, Reuter VE (1994) Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 151: 914–919
Bonkoff H, Stein U, Remberger K (1993) Androgen receptor status in endocrine-paracine cell types of the normal, hyperplastic and neoplastic human prostate. Virch Arch Path 423: 291–294
Cohen M, Arber D, Coffield S, Keegan G, Mellintock J, Sprigths V (1994) Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 74: 1899–1903
Cussenot O, Villette JM, Valeri A, Carion G, Desgrandchamps F, Cortesse A, Meria P, Teillac P, Fiet J, Le Duc A (1996) Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 155: 1340–1343
di Sant’Agnese PA (1998) Neuroendocrine differentiation in prostatic carcinoma: an update. Prostate 8: 74–79
di Sant’Agnese PA (1992) Neuroendocrine differentiation in carcinoma of the prostate. Cancer 70: 254–268
Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC (1990) A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus inmaintanence therapy for extensive-stage small cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 8: 230–240
Faris G, Stein A, Sova Y, Curie M, Lurie A (1995) Chromogranin is a marker for neuroendocrine differentiation in prostate carcinoma of various grades and stages. J Pathol 177: 29–35
Krijen JLM, Bogdanowicz FAT, Seldenrijk CA, Mulder PGH, van der Kwast TH (1997) The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 158:171–174
Oesterling JE, Hanzeur CG, Farrow GM (1992) Small cell anaplastic carcinoma of the prostate. A clinical, pathohistological and immunhistological study of 27 patients. J Urol 147: 804–807
Rubenstein JH, Katin MJ, Mangano MM, Dauphin J, Salenuis SA, Dasoretz DE, Blitzer PH (1997) Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol 20: 376–380
Smith DC, Tucker JA, Trump DL (1992) Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature. J Clin Oncol 10: 499–505
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Neßlauer, T., Triebner, S. & Kleinschmidt, K. Fortgeschrittenes, neuroendokrines Prostatakarzinom. Der Urologe B 39, 510–513 (1999). https://doi.org/10.1007/s001310050327
Published:
Issue Date:
DOI: https://doi.org/10.1007/s001310050327